3,5,7-Trihydroxy-2-[4-hydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 3,5,7-Trihydroxy-2-[4-hydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one
• 化学式: C₂₁H₂₀O₁₂
• 分子量: 464.4
• InChiKey: YLWQTYZKYGNKPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  207
• 氢给体数：
  8
• 氢受体数：
  12

文献信息

• 4-methylcatechol Derivatives and Uses Thereof
  申请人：THANARES GMBH

  公开号：US20160347782A1

  公开（公告）日：2016-12-01

  The invention relates to phenoxy derivatives with glycosidically bound sugar moieties, pharmaceutical compositions containing such compounds, uses of such compounds and compositions, and methods of making such compounds and pharmaceutical compositions.

  这项发明涉及具有糖苷键结合的苯氧基衍生物，包含这些化合物的药物组合物，这些化合物和组合物的用途，以及制备这些化合物和药物组合物的方法。
• MANAGEMENT AND TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
  申请人：CSIR

  公开号：EP2214688A2

  公开（公告）日：2010-08-11
• PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE
  申请人：Müller-Kuhrt Lutz

  公开号：US20100279961A1

  公开（公告）日：2010-11-04

  The invention relates to a pharmaceutical composition comprising a glucuronate, glucoside, and/or sulfo conjugate of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or such a conjugate of a derivative of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or a physiologically well tolerated salt of such a conjugate.
• US9061023B2
  申请人：——

  公开号：US9061023B2

  公开（公告）日：2015-06-23
• [EN] MANAGEMENT AND TREATMENT OF BENIGN PROSTATIC HYPERPLASIA<br/>[FR] CONTRÔLE ET TRAITEMENT DE L'HYPERPLASIE PROSTATIQUE BÉNIGNE
  申请人：CSIR

  公开号：WO2009053857A2

  公开（公告）日：2009-04-30

  The invention provides the use of an extract of a plant of the genus Elephantorrhiza and at least one compound selected from quercitin-3´-O-glucoside, trans-3-O-galloyl-3,3',5,5',7-pentahydroxyflavan, taxifolin-3´-O-glucoside, catechin and epicatechin in the preparation of a medicament for the treatment of benign prostatic hyperplasia (BPH). The mode of action is by a route selected from blocking the conversion of testosterone to dihydrotestosterone by inhibiting the 5α-reductase enzyme or by reducing oxidative stress or both.